Myeloma News and Research

RSS

Proepithelin encourages cell growth and migration in prostate cancer

Researchers from Thomas Jefferson University have identified a protein that appears to play a significant role in the growth and migration of prostate cancer cells, especially androgen-independent prostate cancer cells.

26 Feb 2009

Trial of Quadramet (153 Samarium-lexidronam) in combo with Velcade shows positive results

Quadramet (153 Samarium-lexidronam) is a radioactive medication that targets the bone, specifically bone cancer, and is used to treat pain caused by cancer that has metastasized or spread to the bone.

15 Feb 2009

New drug short-circuits cancer growth

A new drug that blocks cancer's main source of growth has been created in the lab and proven effective in mice, scientists are reporting.

10 Feb 2009

Green tea may counteract anticancer effects of cancer therapy, bortezomib (Velcade)

Green tea products have become regarded as a valuable health supplement, as studies have shown evidence of its benefit against a variety of diseases, including cancer.

3 Feb 2009

Stress may speed growth of melanoma tumors

For patients with a particularly aggressive form of skin cancer - malignant melanoma - stress, including that which comes from simply hearing that diagnosis, might amplify the progression of their disease.

2 Feb 2009

Virotherapy treatment kills prostate cancer cells

A new study appearing in The Prostate has found that certain measles virus vaccine strain derivatives, including a strain known as MV-CEA, may prove to be an effective treatment for patients with advanced prostate cancer.

21 Jan 2009

Sun Pharmaceutical receives FDA approvals for 4 generics

Sun Pharmaceutical Industries Ltd. announced that together with its subsidiaries, it has received final approval from U.S. FDA for several Abbreviated New Drug Applications (ANDA).

7 Jan 2009

Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2

Cylene Pharmaceuticals announced today that it has initiated a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman's disease, or multiple myeloma.

5 Jan 2009

Extract from grapes kills lab leukemia cells, proving value of natural compounds

An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky.

1 Jan 2009

New therapy for transplant rejection

Researchers in the U.S. have discovered a new cancer drug which effectively treats transplant rejections.

29 Dec 2008

FDA approves Mozobil (plerixafor) for multiple myeloma or non-Hodgkin's lymphomas

The U.S. Food and Drug Administration has approved Mozobil (plerixafor), a drug that helps increase the number of blood stem cells for bone marrow transplantation in patients with certain forms of blood cancer.

18 Dec 2008

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone.

14 Dec 2008

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

14 Dec 2008

$Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma$

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.

10 Dec 2008

Xencor presents data on anti-CD19 and anti-CD40 antibodies

Xencor, Inc. presented results Sunday at the 50th Annual Meeting of the American Society of Hematology from pre-clinical studies evaluating XmAb 5574, a monoclonal antibody engineered using Xencor's XmAb Fc technologies that targets the antigen CD19.

10 Dec 2008

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.

10 Dec 2008

Intense chemo wards off recurrence in half of mantle cell lymphoma patients after seven years

More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

10 Dec 2008

$EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients$

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

EntreMed, Inc. has announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients.

10 Dec 2008

Drug combo improves or stabilizes disease for relapsed multiple myeloma patients

Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment.

10 Dec 2008

Lenalidomide safe for elderly patients with chronic lymphocytic leukemia

The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology.

8 Dec 2008

Myeloma News and Research

Proepithelin encourages cell growth and migration in prostate cancer

Trial of Quadramet (153 Samarium-lexidronam) in combo with Velcade shows positive results

New drug short-circuits cancer growth

Green tea may counteract anticancer effects of cancer therapy, bortezomib (Velcade)

Stress may speed growth of melanoma tumors

Virotherapy treatment kills prostate cancer cells

Sun Pharmaceutical receives FDA approvals for 4 generics

Cylene Pharmaceuticals starts CX-4945 trial - first-in class inhibitor of CK2

Extract from grapes kills lab leukemia cells, proving value of natural compounds

New therapy for transplant rejection

FDA approves Mozobil (plerixafor) for multiple myeloma or non-Hodgkin's lymphomas

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Xencor presents data on anti-CD19 and anti-CD40 antibodies

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Intense chemo wards off recurrence in half of mantle cell lymphoma patients after seven years

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

Drug combo improves or stabilizes disease for relapsed multiple myeloma patients

Lenalidomide safe for elderly patients with chronic lymphocytic leukemia

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News